Contact us
Sichuan Welltzpharm Inc.
Zip code:610041
Add:Rm. 601, Bilg B5, TianFu Science Life Park, 88 South Keyuan Road, Hightech Area, Chengdu, Sichuan
Hot news
Current position:Home > Hot news >
2020 global bio-pharmaceutical market will reach $ 287.14 billion
Release time:2015-09-01   Source:Floating meters hfoom   Hits:

    Biological agents (Biological Drug) usually derived from living cells, for the treatment and prevention of various diseases, such as cancer, blood-related diseases, autoimmune diseases and other diseases. Biological agents include therapeutic proteins, monoclonal antibodies (mAb), vaccines. Compared with traditional chemical drugs, biological drugs have a more complex structure and highly sensitive identification and production more difficult, in the production process is usually carried out as many as 250 process monitoring, and chemical drugs are often detected only 50 .

    According to a new report from the world's leading market research company PMR (Persistence Market Research) recently released a market capitalization of global bio-pharmaceutical market in 2014 was $ 161.05 billion, over the next seven years (2014-2020), the market will grow 10.1 percent of compound annual growth rate (CAGR) growth, and reached $ 287.14 billion in 2020. The market capitalization at $ 101.66 billion in 2009, market capitalization of $ 146.55 billion in 2013, 2009 - 2013 CAGR of 9.6%.
    Increasing global aging population, the incidence of chronic disease year after year, a substantial increase in biopharmaceutical clinical demand, is the main driving force to promote the global biopharmaceutical market of rapid development. In addition, governments associations also helped promote the clinical use of biological drugs, and tremendous progress in biomedical aspects, further support the tremendous growth potential of the global biopharmaceuticals market; wherein the anti-vascular endothelial growth factor (VEGF) therapy and genetically modified organisms ( GMOs) position in the biopharmaceutical market is growing. On the other hand, the high cost of biopharmaceuticals and blockbuster patent cliff hindered the development of the global bio-pharmaceutical market; and the biological side-effects and risks associated with injectable drugs, is one of the factors limiting the global biopharmaceutical market.
    According to the report, by category, biopharmaceuticals can be divided into therapeutic proteins, monoclonal antibodies (mAb), vaccines. Among them, the Amgen (Amgen) of Enbrel (etanercept, etanercept) is the world's largest and fastest growing share of therapeutic proteins, Abbvie (AbbVie) of Humira (adalimumab, adalimumab) is the world's largest share and fastest growing monoclonal antibody, Pfizer (Pfizer) of 13-valent pneumococcal vaccine Prevnar 13 (Pei children 13) is the world's largest and fastest growing share of vaccines.
    Geographical division, North America has the largest market share, followed by Europe and Asia. Meanwhile, the growth rate of the North American market is also the fastest, biological drugs such as cancer, diabetes, chronic diseases in the clinical treatment of a wide range of applications, and promote the rapid development of the region's market. For example, a number of clinics in the region are actively promoting the use of biological drugs to treat a variety of chronic diseases, including the United States Biomedical Center (ACBM) is one of the nation's largest bio-medicine clinic. In addition, in 2012, the American Rheumatism Association (ACR) has recommended biological agents and disease-modifying therapy for the treatment of rheumatoid arthritis.
    In Europe, population aging is driving growth in the region biopharmaceuticals market. According to the UN report, in 2000, the aging German population has 23.2% of the total population, and this proportion will reach 33.2% in 2025. Aging can cause some diseases of aging, such as age-related macular degeneration and glaucoma, these age-related diseases requires effective biological medicines for treatment.
    In Asia, low manufacturing costs are attracting many bio-manufacturing investment to support the growth of the region's bio-pharmaceutical market. Asian governments are also being encouraged and biotech companies to increase investment in R & D and production facilities construction, to help promote the market growth in the region. For example, the Swiss biotechnology company Lonza (Lonza) has invested $ 350 million in Singapore and India, to support the production of biological drugs-related.
    The report notes that the major players in the global biopharmaceutical market include: Pfizer, Abbott, Novartis, Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Amgen, Baxter, Biogen Idec (Biogen Idec).
(By floating rice network)